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Résumé en
anglais
P2Y12 receptor inhibitors are antiplatelet agents commonly prescribed in the
treatment of coronary artery disease. Their efficacy can be limited by high on-
treatment platelet reactivity (HPR), which can be evaluated by different biological
assays. Most commonly, HPR is evaluated by flow cytometric vasodilator-stimulated
phosphoprotein-phosphorylation (VASP-P) assay, which can be time consuming. To
evaluate the potential interest of novel technologies, we compared four different
assays. Ninety patients receiving P2Y12 inhibitors were included. Four technologies
were evaluated: the current standard test measuring VASP-P by flow cytometry, the
historical reference test based on light transmittance aggregation (LTA), and two
relatively novel techniques: whole blood multiple electrode aggregometry (MEA) and
platelet function analyzer (PFA), which are less time consuming. The three latter tests
were compared with the VASP-P assay as a reference using receiver operating
characteristics (ROC) analysis: LTA has an excellent comparability with the VASP test
(ROC AUC > 0.9); the other two tests (multiplate and PFA) have only satisfactory
comparability (ROC AUC around 0.7) and therefore may not replace the VASP "gold
standard" test, if importance is attached to a quantitative assessment of the
substitution parameter of VASP. Nevertheless, if a binary approach of the anti-
aggregation result is sought, then one can conclude that the three tests are equivalent
since Cohen's kappa coefficients are very close for the three tests (k = 0.548 for LTA;
k = 0.554 for MEA; k = 0.570 for PFA/P2Y), and a similar proportion of patients are
misclassified (15% for LTA, 14% for MEA, and 13.6% for PFA). Discriminant factor
analysis using all the parameters provided by each test did not improve the diagnostic
performance of MEA or PFA. In conclusion, only LTA shows a good comparability to the
VASP assay using ROC curve analysis, probably because misclassified patients have
results close to the cutoff values. All three tests have moderate agreement regarding
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